Introduction
============

The ketogenic diet (KD) is a high-fat, low-carbohydrate, moderate protein therapy that shifts energy production away from glucose-based and toward ketone-based ATP production. It is effective in treating pharmacoresistant epilepsy ([@B54]; [@B61]; [@B11]) and growing evidence supports its beneficial effects in diverse disorders ([@B71]; [@B68]; [@B2]) and in healthspan and lifespan ([@B55]; [@B58]). As the fundamental mechanism(s) underlying its success remain unclear, molecular changes induced by the diet must be characterized in healthy cells.

Recently we proposed that the broad effectiveness of the KD is related to increased levels of the coenzyme nicotinamide adenine dinucleotide (NAD) ([@B18]), a pivotal molecule for redox reactions and the backbone of ATP generation. Because fewer NAD molecules are reduced during ketone-based vs. glucose-based metabolism in brain, elevated levels of the oxidized form (NAD^+^) can be expected. Consistent with this prediction, we demonstrated that KD can induce rapid and sustained changes in the NAD^+^/NADH ratio in rat hippocampus - an energetically demanding brain region considered a seizure gate ([@B26]) - but not in the cerebral cortex ([@B18]). Similar results have been found in aged mice with a ketone ester supplemented diet ([@B57]).

Elevated NAD^+^ limits seizures and mediates lifespan extension ([@B43]; [@B51]; [@B44]). Experimentally increased NAD^+^ levels enhance mitochondrial function, protect against oxidative stress damage and decrease cell death ([@B38]), diverse effects that could be linked to downstream pathways. NAD^+^ serves as a substrate for two enzyme groups, sirtuins and poly(ADP-ribose) polymerases (PARPs), that affect diverse cellular functions ranging from gene expression to DNA repair ([@B7]).

The NAD^+^-dependent sirtuin enzymes are important regulators of metabolism, inflammation, and DNA repair ([@B50]). Sirt1 is involved in the deacetylation of transcription factors, growth factors, anti-apoptotic, and anti-inflammatory proteins ([@B70]). Sirt1 is essential for normal cognition, preservation of memory and neuronal plasticity ([@B49]). Interestingly, Sirt1 has seizure-suppressing effects in animal models of epilepsy ([@B66]) and mediates benefits of caloric restriction, such as lifespan extension and promotion of cell survival ([@B42]; [@B14]; [@B60]). Sirt6 and Sirt7 participate directly in base-excision repair of DNA, thus decreasing age-associated DNA damage ([@B53]; [@B65]).

PARP enzymes add polymers of ADP-ribose to nuclear proteins in an NAD^+^-dependent matter and are major consumers of NAD^+^. PARP-1 plays an important role in cell survival and DNA damage repair ([@B23]; [@B17]). DNA oxidation by reactive oxygen species induces a steady-state level of DNA damage and is a by-product of normal cellular metabolism. PARP-1 is a molecular sensor for this type of DNA damage and both its activity and protein levels are affected directly by cellular levels of oxidative DNA damage ([@B16]; [@B9]; [@B62]). Although PARP enzymes play a vital role in DNA repair, their over-activation (and subsequent depletion of NAD^+^) has been linked to diverse neuropathological conditions ([@B52]; [@B47]).

Since the KD rapidly increases NAD^+^ levels ([@B18]) and changes in NAD^+^ levels modulate the activity of the abovementioned enzymatic pathways, we hypothesized that consumption of a KD would lead to downstream beneficial changes in NAD^+^-dependent enzymes' activity in rat hippocampus.

Materials and Methods {#s1}
=====================

Animals and Dietary Treatment
-----------------------------

Sprague-Dawley male rats (age 11--14 week; 350--550 g; *n* = 22) were pair-housed at Trinity College, with water and food *ad libitum*. Animals received either a high-carbohydrate chow diet (Purina 5001, PharmaServ, Framingham, MA, United States) (CD), or a 6:1 (fat:protein+carbohydrates) KD (F3666, Bio-Serv, Frenchtown, NJ, United States) for 2 days (2d) or 3 weeks (3w); (*n* = 8 each). At the end of dietary treatment, animals were sacrificed, trunk blood was collected and the hippocampi were dissected. Plasma β-hydroxybutyrate was measured using Precision Xtra monitors (Abbott Laboratories; Abbott Park, Chicago, IL, United States). All experiments were in compliance with National Institutes of Health Guides and Trinity College Animal Care and Use Committee.

NAD^+^/NADH Analysis
--------------------

Analysis was done according to manufacturer's instructions (Sigma-Aldrich, United States) as previously described ([@B18]). Optical density of NAD^+^/NADH and NADH were obtained at 450 nm. NAD^+^ values were calculated by subtracting NADH values from total NAD values and normalized to protein concentrations.

Sirtuin Activity
----------------

Hippocampal tissues were homogenized in PBS lysis buffer \[137 mM NaCl, 2.7 mM KCl, 10 mM Tris pH 7.4, 1 mM PMSF, 1:1000 Protease inhibitor cocktail (PIC)\]. Pellets were suspended in Extraction lysis buffer (20 mM Tris pH 7.8, 125 mM NaCl, 5 mM MgCl~2,~ 0.2 mM EDTA, 0.1% NP40, 12% glycerol, 200 mM PMSF, 200 mM DDT, 1:1000 PIC) and sonicated. After centrifugation, combined activity of nuclear sirtuin enzymes (Sirt1,6,7) was measured in hippocampal nuclear extracts following manufacturer's instruction (Epigentek, United States).

Real-Time PCR
-------------

Total hippocampal RNA (1 μg) was extracted (Qiagen, United States), reverse transcribed (Applied Biosystems, United States), and relative mRNA levels were detected by quantitative PCR (StepOnePlus, Thermo Fisher, United States). Predesigned rat Sirt1, Sirt6, Sirt7, and β-actin TaqMan Gene Expression probes (Assay IDs: Rn01428096_m1, Rn01408249_m1, Rn01471420_m1, and Rn00667869_m1, respectively) were used with TaqMan Gene Expression Master Mix (Thermo Fisher, United States). Analyses were performed using the standard curve method with Sirt transcripts normalized to β-actin as the endogenous control.

Western Blot
------------

Hippocampal homogenates made in RIPA buffer were analyzed by western blot for PARP-1 (Cell Signaling) and β-actin (Neomarkers) proteins (1:1000 primary antibodies). Blots were revealed by Chemiluminescence (Thermo Fisher, United States) and quantified using ImageJ software (National Institutes of Health, Bethesda, MD, United States).

DNA Damage Analysis
-------------------

Purified DNA was obtained from hippocampal cells (DNeasy Blood and Tissue kit, Qiagen, United States) and levels of 8-OHdG (8-hydroxy-2′-deoxyguanosine) were quantified by competitive ELISA assay (StressMarq, United States) following manufacturer's protocol.

Statistical Analysis
--------------------

One-way ANOVA and *post hoc* Tukey's multiple comparisons test were performed for all experiments using GraphPad Prism software (GraphPad, United States). Data are expressed as mean ± SEM representing the average of two measurements per sample using the animal number indicated as subject number. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001, non-significant (ns).

Results
=======

To re-establish previous observations on rapid and sustained KD-induced increases in NAD^+^ availability ([@B18]), we treated a new cohort of rats with control diet or KD. In addition to replicating increased circulating ketones (mM: 0.76 ± 0.15 2d KD, 0.67 ± 0.23 3w KD, 0.05 ± 0.02 CD; *p* = 0.0189) and NAD^+^/NADH ratios in response to KD (**Figure [1A](#F1){ref-type="fig"}**), we established that the increase in ratio was solely due to an increase in the oxidized form of NAD (**Figure [1B](#F1){ref-type="fig"}**).

![Hippocampal changes in NAD and sirtuins after ketogenic diet (KD) treatment. **(A,B)** NAD^+^/NADH ratios and NAD^+^ levels in the hippocampus after standard chow diet (CD; *n* = 5), 2 day (2d; *n* = 7), or 3 weeks KD treatment (3w; *n* = 7). **(C)** Collective deacetylation activity of Sirt1, Sirt6, and Sirt7 enzymes. A significant increase was observed at 2d and remained elevated at 3w. *n* = 6--8 animals (*n* = 2 per animal). **(D--F)** Real-time PCR analysis of Sirt1,--6,--7 gene expression in hippocampus. Sirt1 expression was increased only at 2d of treatment. CD, *n* = 6; 2d KD, *n* = 8; 3w KD, *n* = 8 (*n* = 2 per animal).](fncel-12-00263-g001){#F1}

To address downstream effects sirtuin enzymes' activity, and expression, which depend directly on the levels of the main substrate NAD^+^ ([@B39]; [@B12]), were examined and the collective deacetylation activity of nuclear sirtuin enzymes (Sirt1, Sirt6, Sirt7) was measured in hippocampal nuclear extracts. As shown in **Figure [1C](#F1){ref-type="fig"}**, a rapid, robust increase in sirtuins' activity was detected at 2d of KD treatment compared to control, and remained elevated at 3w, albeit reduced. Changes in enzymatic activity could be reflective of alterations in gene expression of one or more of these enzymes. Analysis of nuclear sirtuins expression levels showed that Sirt1 mRNA was increased in animals fed a KD for 2d compared to control diet but normalized after 3w of treatment (**Figure [1D](#F1){ref-type="fig"}**). No significant mRNA changes were observed for Sirt6 and Sirt7 (**Figures [1E,F](#F1){ref-type="fig"}**).

NAD^+^ also serves as main substrate for PARP-1, an enzyme that functions as a DNA damage sensor and participates in DNA repair. We, therefore, examined potential changes in the hippocampal DNA damage response after KD treatment. A rapid and dramatic decline in PARP-1 protein level was detected after 2d, with further reduction upon longer KD exposure (**Figure [2A](#F2){ref-type="fig"}**). Although PARP-1 is a major consumer of NAD^+^, the activity and protein levels of this enzyme are modulated primarily by levels of oxidative DNA damage ([@B16]; [@B62]). Therefore DNA damage in hippocampal tissue was assessed further by quantification of 8-OHdG, a critical biomarker of oxidative stress. Dietary treatment with 2d KD decreased the levels of 8-OHdG, and a 3w treatment led to a further decrease in this biomarker (**Figure [2B](#F2){ref-type="fig"}**). PARP-1 protein levels strongly correlated with the changes in oxidative DNA damage here detected ([@B46]; [@B29]). Together, observed decreases in PARP-1 and 8-OHdG levels suggest that consuming a KD decreases oxidative DNA damage.

![Effect of KD treatment on hippocampal PARP-1 levels and 8-OHdG levels. **(A)** Quantification of normalized PARP-1 protein levels in hippocampi obtained from animals fed standard chow (CD), or KD for 2d or 3w. Representative image of PARP-1 Western blot included. Each lane represents an individual animal. Blots were repeated 2--3 times. **(B)** Significant and progressive decrease in 8-OHdG levels was observed in hippocampi obtained from KD treated animals. CD, *n* = 6; 2d KD, *n* = 8; 3w KD, *n* = 8 (*n* = 2 for each animal).](fncel-12-00263-g002){#F2}

Discussion
==========

Here we determined that KD increased NAD^+^, decreased levels of DNA damage and induced rapid changes in PARP-1 and sirtuin enzymes. This cohort of changes induced within 2 days of KD exposure could thus be protective for healthy cells against oxidative and metabolic damage and provide key mechanisms rendering KD beneficial across a range of neurological conditions.

The time-course of changes in Sirt1 activity and expression parallel the persistent increase in NAD^+^ levels ([@B18]) and support the idea that elevated NAD^+^ increases activation of sirtuin enzymes. The ability of Sirt1 to affect the expression of genes implicated in a variety of functions ranging from neuroinflammation to proliferation and apoptosis ([@B13]; [@B31]) could explain the KD's ability to impact diverse cellular pathways. Sirt1 activity reduces cell death and inflammation ([@B72]; [@B34]) and increases neuronal survival and life-span ([@B14]; [@B37]; [@B36]). Therefore beneficial effects of ketogenic treatment in decreasing inflammation and combating neurodegenerative diseases could be attributed to these molecular mechanisms ([@B21]; [@B59]; [@B33]).

Several genes controlling ketosis, fatty acid oxidation, and mitochondrial biogenesis are upregulated after long periods of KD treatment ([@B15]; [@B8]; [@B35]). Augmented sirtuin enzymatic activity without enhanced gene expression observed at 3 weeks may be due to elevated levels of the substrate NAD^+^. As Sirt1 was found to play a role in hepatocellular lipid metabolism ([@B27]), the transient upregulation of Sirt1 could be a cellular response to the shift in energy metabolism from glucose to fatty acids and disappear after adaptation occurs.

Previous work illustrated that ketogenic treatment reduced reactive oxygen species ([@B45]; [@B22]). Notably, Sirt1 can prevent neuronal cell death by reducing oxidative stress ([@B36]; [@B63]) which has been implicated in several neurodegenerative disorders ([@B1]; [@B24]; [@B32]; [@B30]). A consequence of oxidative stress and impaired mitochondrial function is DNA damage ([@B6]). This type of oxidative damage occurs as a by-product of normal cellular respiration, and can significantly contribute to the process of aging and neurodegeneration ([@B69]). Moderate DNA damage triggers PARP-1 activation and DNA repair, resulting in reduced 8-OHdG levels ([@B25]). Our quantified decrease in 8-OHdG and correlated PARP-1 changes suggest that ketogenic therapy can also rapidly and directly modulate DNA repair and oxidative stress. Therefore, potential direct effects, as well as elevation of Sirt activity and/or NAD^+^ inhibiting DNA damage ([@B28]) and decreasing reactive oxygen species ([@B43]; [@B4]; [@B38]) could contribute to decreased DNA damage. Interestingly, inhibition of PARP-1 can enhance mitochondrial metabolism and activate Sirt1 enzyme ([@B3]). Thus our data reinforce the existence of cross-talk between Sirt1 and PARP-1 ([@B10]), possibly triggered by KD treatment, and modulated by NAD^+^ levels ([@B19]; [@B25]; [@B48]).

The rapid response of NAD^+^ and downstream effectors may relate to the anti-seizure response found in some patients after just a few days of KD treatment ([@B20]; [@B11]). Moreover, elevation in PARP-1 activity, accompanied by NAD^+^ depletion and reduced Sirt1 activity, was shown to mediate neuronal death after seizure induction in animal models ([@B67]). Our data point to an opposite effect of KD on these three cellular measures, thus hinting at these effects as potential anti-seizure mechanisms. In addition, neuronal cell death and hippocampal 8-OHdG levels were increased following kainate-induced seizures in rats and prevented by administration of antioxidants ([@B41]). The KD's ability to modulate oxidative DNA damage and reduce 8-OHdG levels in the hippocampus suggests that KD treatment may also be protective against seizure-induced neuronal death and DNA damage.

Here we quantified altered endogenous NAD^+^ levels and key downstream effectors as a direct result of consuming a KD and offered key potential mechanisms underlying anti-seizure and neuroprotective effects of ketogenic therapy. The changes found in disease-free animals in our current and previous studies ([@B18]) indicate that the use of ketone bodies as an energy source can be associated with a healthier metabolic phenotype and an enhanced redox state even in the absence of disease or senescence. Furthermore, the NAD^+^ precursor nicotinamide ribose and PARP inhibitors are proposed to combat cancer and a host of inflammatory and neurodegenerative diseases ([@B5]; [@B40]; [@B56]; [@B64]). We provide evidence that consuming a KD can mobilize similar mechanisms, and promote the metabolic resilience necessary to combat neurodegenerative and age-associated diseases.
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